The Role of Intestinal Barrier Function in Overweight Patients with IBS with Diarrhea Undergoing a Long-Term Low Fermentable Oligo-, Di-, and Monosaccharide and Polyol Diet
Nutrients · 2023
DOI: 10.3390/nu15214683 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nutrients, 2023. Verfasst von Michele Linsalata und 9 weiteren Autor:innen. Beteiligte Einrichtung: Functional Gastrointestinal Disorders Research Group, National Institute of Gastroenterology IRCCS "S. de Bellis", 70013 Metropolitan, Italy. Hauptthemen laut MEDLINE: Irritable Bowel Syndrome. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Italian Ministry of Health, Italian Ministry of Health RC 2020–2021, Prog. N° 16.
Abstract (Originalsprache)
Overweight and obesity have been suggested as significant factors in irritable bowel syndrome (IBS) development. However, the relationship between overweight/obesity and IBS is unclear. It is known that a modified intestinal barrier, especially the permeability of the small intestine (s-IP), can play a significant role in the pathogenesis of both obesity and IBS. Moreover, dietary interventions are essential for treating both pathologies. We evaluated the gastrointestinal (GI) symptoms and the urinary and circulating markers of GI barrier function and integrity, the markers of intestinal dysbiosis and bacterial translocation, in 40 IBS patients with predominant diarrhea (IBS-D) (32 females and 8 males; mean age = 43.5 ± 1.4 years), categorized using their Body Mass Index levels as normal (NW) and overweight (OW). Evaluations were performed before and after 12 weeks of a Low FODMAP Diet (LFD). At the baseline, OW patients showed a significantly higher s-IP than NW. After an LFD, a significant improvement of s-IP in OW patients occurred, along with a significant decrease in markers of epithelial integrity and bacterial translocation. Our findings highlight the close relationship between overweight and the intestinal barrier and support their involvement in IBS-D pathophysiology. Furthermore, the positive role of an LFD in managing overweight IBS-D was highlighted.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Functional Gastrointestinal Disorders Research Group, National Institute of Gastroenterology IRCCS "S. de Bellis", 70013 Metropolitan, Italy.
- Section of Gastroenterology, Department of Precision and Regenerative Medicine and Ionian Area, University of Bari, 70124 Bari, Italy.
- Scientific Direction, National Institute of Gastroenterology IRCCS "S. de Bellis", 70013 Metropolitan, Italy.
ORCID-Profile: Michele Linsalata, Giuseppe Riezzo, Antonella Orlando, Benedetta D'Attoma, Giuseppe Losurdo, Alfredo Di Leo, Gianluigi Giannelli, Francesco Russo
Förderung
- Italian Ministry of Health
- Italian Ministry of Health RC 2020–2021, Prog. N° 16
Zitieren
APA
Linsalata, M., Riezzo, G., Orlando, A., D'Attoma, B., Prospero, L., Ignazzi, A., Losurdo, G., Di Leo, A., Giannelli, G., & Russo, F. (2023). The Role of Intestinal Barrier Function in Overweight Patients with IBS with Diarrhea Undergoing a Long-Term Low Fermentable Oligo-, Di-, and Monosaccharide and Polyol Diet. Nutrients. https://doi.org/10.3390/nu15214683
Vancouver
Linsalata M, Riezzo G, Orlando A, D'Attoma B, Prospero L, Ignazzi A, et al. The Role of Intestinal Barrier Function in Overweight Patients with IBS with Diarrhea Undergoing a Long-Term Low Fermentable Oligo-, Di-, and Monosaccharide and Polyol Diet. Nutrients. 2023. doi:10.3390/nu15214683
BibTeX
@article{Linsalata2023,
author = {Linsalata, Michele and Riezzo, Giuseppe and Orlando, Antonella and D'Attoma, Benedetta and Prospero, Laura and Ignazzi, Antonia and Losurdo, Giuseppe and Di Leo, Alfredo and Giannelli, Gianluigi and Russo, Francesco},
title = {The Role of Intestinal Barrier Function in Overweight Patients with IBS with Diarrhea Undergoing a Long-Term Low Fermentable Oligo-, Di-, and Monosaccharide and Polyol Diet},
journal = {Nutrients},
year = {2023},
doi = {10.3390/nu15214683}
}
EUVIMED